Comment on: "Adverse drug reaction reporting by patients: an overview of fifty countries".
- Published in:
- 2015
- By:
- Publication type:
- commentary
Works matching IS 01145916 AND DT 2015 AND VI 38 AND IP 1
Results: 19
1
2
Causal assessment of pharmaceutical treatments: why standards of evidence should not be the same for benefits and harms?
- Published in:
- 2015
- By:
- Publication type:
- journal article
3
Comment on: "Desideratum for evidence-based epidemiology".
- Published in:
- 2015
- By:
- Publication type:
- commentary
4
Authors' Reply to Harpaz et al. Comment on: 'Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance'.
- Published in:
- Drug Safety, 2015, v. 38, n. 1, p. 115, doi. 10.1007/s40264-014-0246-8
- By:
- Publication type:
- Article
5
Safety considerations with pharmacological treatment of gestational diabetes mellitus.
- Published in:
- 2015
- By:
- Publication type:
- journal article
6
Authors' reply to Hennessy and Leonard's comment on "Desideratum for evidence-based epidemiology".
- Published in:
- 2015
- By:
- Publication type:
- commentary
7
Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
- Published in:
- 2015
- By:
- Publication type:
- journal article
8
Authors' reply to Harpaz et al. comment on: "Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance".
- Published in:
- 2015
- By:
- Publication type:
- commentary
9
Authors' reply to Ahmad SR: "Adverse drug reaction reporting by patients: an overview of fifty countries".
- Published in:
- 2015
- By:
- Publication type:
- commentary
10
Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?
- Published in:
- 2015
- By:
- Publication type:
- journal article
11
Comment on: 'Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries'.
- Published in:
- Drug Safety, 2015, v. 38, n. 1, p. 109, doi. 10.1007/s40264-014-0241-0
- By:
- Publication type:
- Article
12
Authors' Reply to Ahmad SR: 'Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries'.
- Published in:
- Drug Safety, 2015, v. 38, n. 1, p. 111, doi. 10.1007/s40264-014-0242-z
- By:
- Publication type:
- Article
13
Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment.
- Published in:
- 2015
- By:
- Publication type:
- journal article
14
Comment on: "Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance".
- Published in:
- 2015
- By:
- Publication type:
- commentary
15
Comment on: 'Desideratum for Evidence-Based Epidemiology'.
- Published in:
- Drug Safety, 2015, v. 38, n. 1, p. 101, doi. 10.1007/s40264-014-0252-x
- By:
- Publication type:
- Article
16
Bacillus Calmette-Guérin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system.
- Published in:
- 2015
- By:
- Publication type:
- journal article
17
The US Food and Drug Administration-European Medicines Agency collaboration in pharmacovigilance: common objectives and common challenges.
- Published in:
- 2015
- By:
- Publication type:
- journal article
18
Authors' Reply to Hennessy and Leonard's Comment on 'Desideratum for Evidence-Based Epidemiology'.
- Published in:
- Drug Safety, 2015, v. 38, n. 1, p. 105, doi. 10.1007/s40264-014-0254-8
- By:
- Publication type:
- Article
19
The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.
- Published in:
- 2015
- By:
- Publication type:
- journal article